Sort
39,280 grants matching “leukemia”
Core 2
$673,401Andrea Califano · Columbia University Health Sciences · U54 · FY2013 · CA
REGULATION OF HEMATOPOIETIC PROGENITORS BY DE NOVO DNA METHYLATION
$673,301Margaret Goodell · Baylor College Of Medicine · R01 · FY2022 · DK
Clinical Trials with Immunotoxins
$673,145Ira Pastan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism
$673,119Kun Ping Lu · Beth Israel Deaconess Medical Center · R01 · FY2017 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
$673,092Renata Pasqualini · Rbhs -Cancer Institute Of New Jersey · R01 · FY2018 · CA
Role of HSP90 Family Chaperone Proteins in Cellular Signal Transduction
$672,998Leonard Neckers · Division Of Clinical Sciences - Nci · ZIA · FY2010 · CA
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
$672,991Daniel J. Powell · University Of Pennsylvania · R01 · FY2022 · CA
Viral Noncoding RNAs and Cell Transformation
$672,801Joan A. Steitz · Yale University · R01 · FY2023 · CA
Kansas City Clinical Oncology Program CCOP
$672,441Rakesh Gaur · Nci Community Oncology Research Program · U10 · FY2007 · CA
Th1Th2 and Tc1Tc2 T Cell Subsets in Transplantation Therapy
$672,235Daniel Fowler · Division Of Clinical Sciences - Nci · ZIA · FY2012 · CA
Studies of Host Cellular Proteins Required for viral Budding and release
$672,106Fadila Bouamr · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Glia maturation factor-gamma modulation of signaling pathways in macrophages
$672,071Griffin Rodgers · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL
Mechanisms and therapeutic implications of human clonal hematopoiesis (CH) mutations
$671,875Eirini Papapetrou · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Epigenetics, Signals, and Oxytocin and Vasopressin Gene Expression in the CNS.
$671,841Harold Gainer · National Institute Of Neurological Disorders And Stroke · ZIA · FY2010 · NS
Outcomes for CLL patients treated with novel therapy
$671,624Neil E Kay · Mayo Clinic Rochester · R01 · FY2025 · CA
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias
$671,604Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Developing novel therapies to improve blood stem cell transplantation outcomes
$671,563Ramiro Garzon · University Of Utah · R01 · FY2023 · HL
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
$671,549Jin Wang · Baylor College Of Medicine · R01 · FY2020 · CA
Mechanisms of Virus Entry into Cells and Antiviral Barriers Limiting Entry
$671,484Alex Compton · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$671,440Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2024 · CA
Enhancing Treg Therapeutic Efficacy in GVHD
$671,440Bruce R. Blazar · University Of Minnesota · R01 · FY2024 · HL
KSHV Latency Regulation
$671,213Kenneth M Kaye · Brigham And Women'S Hospital · R01 · FY2025 · AI
Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
$671,104Ehab L Atallah · Medical College Of Wisconsin · R01 · FY2015 · CA
Design of an integrated microdevice to measure malignant lipid signaling in single cells from clinical samples
$671,072Nancy L Allbritton · University Of Washington · R01 · FY2025 · CA
Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms
$670,945Eirini Papapetrou · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA